SYH2070 not checked

CSPC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks”In the company’s words, NCT07695597 on ClinicalTrials.gov
Tested for
Mixed Hyperlipidemia, Diagnosed With HoFH
Main trialPhase 2
“This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.”In the company’s words, NCT07695597 on ClinicalTrials.gov

Other drugs for Mixed Hyperlipidemia

All 14 drugs for Mixed Hyperlipidemia

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Apr 2027 A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
Phase 2Recruiting 16 Sep 2027 Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
Phase 1Recruiting 1 Nov 2026 A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SYH2070

Following is part of Solo: you see every change to SYH2070 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in